Teclison Ltd.
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.teclison.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)β’ Click on a phase to view related trials
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
- Conditions
- Colorectal Cancer; Lung Cancer
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT04701476
- Locations
- πΊπΈ
University of California, Irvine Medical Center, Orange, California, United States
π¨π³China Medical University Hsinchu Hospital, Hsinchu, Taiwan
π¨π³Chung Shan Medical University Hospital, Taichung, Taiwan
Combination of TATE and PD-1 Inhibitor in Liver Cancer
- Conditions
- Hepatocellular CarcinomaGastric Cancer
- Interventions
- Combination Product: Trans-arterial tirapazamine embolization
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT03259867
- Locations
- πΊπΈ
University of California, Irvine, Orange, California, United States
πΊπΈUniversity of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
πΊπΈMedical College of Wisconsin, Milwaukee, Wisconsin, United States
TATE Versus TACE in Intermediate Stage HCC
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03145558
- Locations
- πΊπΈ
University of California, Irvine, Irvine, California, United States
πΊπΈOregon Health Science University, Portland, Oregon, United States
πΊπΈMedical College of Wisconsin, Milwaukee, Wisconsin, United States
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- Conditions
- Hepatocellular CarcinomaGastrointestinal Cancer MetastaticNeuroendocrine Tumors
- Interventions
- Procedure: Conventional Transarterial Embolization (TAE)
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02174549
- Locations
- πΊπΈ
Stanford University, Palo Alto, California, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States